Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Efficacy of salt reduction for managing overactive bladder symptoms: a prospective study in patients with excessive daily salt intake


This study aimed to investigate the efficacy of salt intake restriction on overactive bladder (OAB) symptoms in patients with excessive salt intake. Patients received a brochure on nutritional guidance regarding salt intake reduction and received health education every 4 weeks for 12 weeks. Data from overactive bladder symptom score (OABSS) questionnaires and frequency volume charts (FVCs) were evaluated. The daily salt intake was estimated by determining the urinary sodium and creatinine concentrations using spot urine samples. Of the 98 patients included, 71 (72.4%) successfully restricted their daily salt intake after 12 weeks (salt restricted [R] group), while 27 (27.6%) did not (salt non-restricted [N-R] group). The scores to each OABSS question and the resulting total score improved significantly in the R group; however, the individual scores remained unchanged and the total score increased in the N-R group. The FVC data indicated improved voided volumes in the R group as compared to in the N-R group. Ultimately, 17 (23.9%) patients in the R group no longer fulfilled the OAB diagnostic criteria after salt intake reduction. Thus, salt intake reduction improved urinary symptoms in patients with OAB and may be a therapeutic option for OAB in patients with excessive daily salt intakes.


Overactive bladder (OAB) is a symptom-based syndrome that is characterized by urinary urgency with or without urge incontinence1. Individuals with OAB experience urgency and other lower urinary tract symptoms (LUTS). Data from some epidemiological surveys suggest that the prevalence of OAB is between 16 and 19%2,3,4. In clinical practice, anticholinergic agents and/or β3 adrenergic agonists are often prescribed to patients with OAB; however, adverse events may occur due to the deterioration of physiological function, especially in the elderly, and administering additional oral medications would be difficult.

Poor eating habits can cause lifestyle-related diseases and the metabolic syndrome (MetS), which can contribute to the onset of OAB5. In addition, a routinely excessive salt intake is associated with MetS and lifestyle-related diseases (including hypertension, chronic kidney dysfunction, and diabetes mellitus), and induces symptoms associated with OAB6,7. Hence, improving the dietary habits might be an effective treatment option for OAB. In fact, some researchers have reported a relationship between diet and OAB8,9; however, little is known about the mechanism of OAB control following dietary improvements10,11.

We previously reported that reducing the salt intake improved nocturia and nocturnal polyuria12. Consequently, we have focused on the dietary modifications that may improve urinary disorders. Basic research using several animal models has shown that an excessive salt intake enhances the expression of oxidative stress genes and neurotransmitters and induces bladder ischemia, which causes OAB13,14. Furthermore, salt reduction has been shown to improve LUTS and these risk factors13,14. However, the effect of salt reduction on OAB in humans is not well understood. We hypothesized that salt intake reduction is a useful approach for managing OAB. Hence, the aim of this study was to examine the efficacy of salt intake restriction for the management of OAB in patients with excessive salt intakes.


Patients and nutritional guidance

This study was approved by our institution’s ethical committee. All participants who lived in Nagasaki city, Nagasaki, Japan provided a written informed consent. This prospective clinical study was performed from September 2014 to March 2015. Patients were included if they: (1) had symptoms of OAB for at least 3 months (overactive bladder symptom score [OABSS] ≥ 2 for urgency and a total OABSS ≥ 315), (2) were either not taking any medications for OAB or were not responding satisfactorily to β3 adrenergic receptor agonists and/or anticholinergic agents for at least 3 months (OABSS: urgency ≥ 2, total score ≥ 3), and (3) had excessive salt intake, i.e., ≥ 8 g/day for men and 7 g/day for women16. Patients were excluded if they: (1) had acute urinary tract infections, (2) had any condition that affected the urinary function (including a history of pelvic surgery, radiation therapy, urethral strictures, pelvic organ prolapse, urological malignancies, or a neurogenic bladder), (3) were administered medications that could affect sodium (Na) excretion (for example, diuretics and antidiuretic hormone), or (4) had end-stage renal disease (which was defined as an estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). Medications for OAB, such as β3 adrenergic receptor agonists and anticholinergic agents, were continued on the condition that the dose was kept constant during the study period.

The enrolled patients were given a brochure that provided nutritional guidance on salt intake restrictions. The brochure detailed the approximate salt intake from a regular diet and also described the use of salt for seasoning food. Furthermore, the brochure also described how to season food using spices, instead of salt, to limit the salt intake. The study spanned 4 weeks, and the patients received health education from the physicians and nurses every 4 weeks during the study.

Urinary parameters and daily salt intake

To estimate the participants’ daily salt intake, we used morning spot urine samples that comprised of one sample per participant and were provided once a day between 9:00 am and 11:00 am at our institution, as described previously17. Thereafter, to estimate the Na and creatinine (Cr) concentrations in the spot urine samples from the daily salt intake, we used a formula that was adjusted for body height, weight, and age as follows: 24-h Na excretion (mEq/day) = 21.98 (Na S/[Cr S × 10] × Pr.UCr24)0.392 − 2.04 × age (years) + 14.89 × body weight (kg) + 16.14 × height (cm) − 2244.45, where Na S is the Na concentration in the spot urine sample in mEq/L, Cr S is the Cr concentration in the spot urine sample in mg/dL, and Pr.UCr24 is the predicted 24-h urinary Cr excretion in mg/day. This formula appeared to be less affected by the sample collection time, and its accuracy was relatively high.

On the basis of the International Continence Society’s standard, the nocturnal urine volume (NUV) was defined as the total volume of urine passed during the night, including the first morning void. Nocturnal polyuria index (NPi) was defined as the ratio of the nocturnal urine production to the 24-h total urine production. Na concentration in the spot urine test was represented as Na concentration in the spot voiding urine. Renal dysfunction was defined as an eGFR < 60 mL/min/1.73 m2.

We evaluated the objective and subjective urological parameters before and 12 weeks after salt intake reduction. We also evaluated the changes in the OAB using the OABSS questionnaire and assessed the patients’ salt intake by using spot urine samples to estimate their urinary Na excretion. In addition, we asked the participants to complete 3-day frequency volume charts (FVCs), and evaluated the average urinary volumes and voiding frequencies from these data. We defined successful salt reduction as a restriction in the absolute value of the estimated salt intake from baseline to 12 weeks after study initiation. The primary outcome in this study was the effectiveness of a reduction in the salt intake on the total OABSS scores in OAB patients who successfully reduced their salt intake. The secondary endpoints were the effects on each parameter in the OABSS list, objective findings in patients who successfully reduced their salt intake, and comparative subjective and objective findings between patients who reduced and did not reduce their salt intake successfully.

Statistical analyses

The number of samples was determined on the basis of our previous report12. In our previous study, the success rate of salt reduction in the study subjects was 69.5%. Hence, we set a probability of 0.05 (two-sided), a power of 80%, and an effect size of 0.5. We estimated that the ideal number of participants for this study should be at least 75. All data are expressed as means ± standard deviations. The Student's t-test was used to compare the continuous parametric variables between patients with and without successful salt restriction. All statistical tests were performed using JMP, version 13 (SAS Institute Inc., Cary, NC, USA).

Research involving human participants

This study was approved by the Nagasaki University Hospital Ethical Committee and carried out in accordance with the principles of the Declaration of Helsinki. All participants provided a written informed consent.


Patients’ characteristics

A total of 98 patients (comprising of 52 men and 46 women) who fulfilled the criteria for OAB were enrolled in the study. As shown in Table 1, the mean age was 66.7 ± 11.5 years. Around 71 patients (72.4%) successfully reduced their salt intake and were included in the salt restricted (R) group, while 27 patients (27.6%) did not succeed in reducing their salt intake and were included in the salt non-restricted (N-R) group. There were no differences between the two groups in terms of the body mass index or the proportion of comorbidities such as hypertension, diabetes mellitus, and hyperlipidemia. The estimated mean salt intake at baseline was significantly higher in the R group (10.4 ± 2.2 g) than in the N-R group (9.6 ± 0.9 g) (p < 0.001). In this study, there were no missing values in the FVCs, and all items could be analyzed in all patients. Table 1 also shows the differences in the subjective and objective symptoms at baseline between the two groups. Furthermore, the groups did not differ in terms of the urological parameters determined from the 3-day FVCs and the data on subjective symptoms gathered from the OABSS questionnaires.

Table 1 Patients’ characteristics and urological symptoms before salt intake reduction in each group.

Changes in the salt intake volume and the urological parameters assessed using the FVC and OABSS

Table 2 shows the changes in the estimated salt intakes and in the urological parameters determined from the 3-day FVCs. During the study period, the patients in the R group reduced their mean daily salt intake from 10.4 ± 2.2 g/day to 7.7 ± 2.0 g/day (p < 0.001), while the patients in the N-R group increased their mean daily salt intake from 9.6 ± 0.9 g/day to 11.5 ± 1.9 g/day (p < 0.001). According to the 3-day FVC data, in the R group, the mean daytime and nighttime voiding frequencies decreased significantly after nutritional guidance (p < 0.001; Table 2). Conversely, in the N-R group, the mean daytime and nighttime voiding frequencies increased significantly, regardless of whether the patients received nutritional guidance or not (p = 0.015 and 0.043, respectively; Table 2). However, the fluid intake volume in the R group decreased from 2,448.7 ± 699.7 mL/day to 2,066.2 ± 608.0 mL/day (p < 0.001), while the volume in the N-R group increased significantly from 2,463.3 ± 559.4 mL/day to 2,735.2 ± 556.7 mL/day (p < 0.001). Furthermore, the voided volume in the R group increased from 247.8 ± 25.1 mL to 260.4 ± 32.6 mL (p < 0.001), while the voided volume in the N-R group decreased from 240.9 ± 24.0 mL to 238.3 ± 24.1 mL (p = 0.007). The diurnal urine volume, NUV, and NPi decreased significantly after nutritional guidance in the R group; however, a significant decrease was not found in the diurnal urine volume of the N-R group (Table 2). Furthermore, the changes in the least square mean of the NPi from the baseline to 12 weeks later were -8.5% in the R-group and -0.2% in the N-R group (P = 0.012).

Table 2 Changes in salt intake volume and urological parameters including overactive bladder symptom scorer between two groups.

After the 12-week nutritional guidance, the questionnaire scores for the OAB symptoms and the total OABSS improved in the R group (Table 2). However, the questionnaire scores for the OAB symptoms did not change and the total OABSS increased after 12 weeks in the N-R group. Of the 98 patients included, 26 (26.5%) experienced an improvement in the OABSS for urgency by 1 point or more. Furthermore, the urgency score decreased in 24 patients (33.8%) and 2 patients (7.4%) in the R and N-R groups, respectively; this difference in the reduction was statistically significant (P = 0.001). After the 12-week study period, 17 patients (23.9%) in the R group no longer met the criteria used to define OAB in this study, while none of the patients in the N-R group deviated from these criteria.


The present study’s findings showed that reducing the salt intake effectively improved the subjective and objective symptoms in patients with OAB whose daily salt intake was excessive. In addition, while some patients in the R group no longer met the criteria for OAB diagnosis after the 12-week study, none of the OAB symptoms improved in the N-R group. Many researchers have reported that MetS and lifestyle-related diseases are involved in the development of LUTS, including OAB6,7,12. In addition, typical lifestyle-related diseases, for example, hypertension, diabetes, and dyslipidemia, are strongly associated with an excessive daily salt intake10,11. Indeed, in a previous study, we reported that an excessive daily salt intake was closely associated with LUTS, including nocturia18. We found a significantly positive association between nocturnal polyuria and the salt intake and lower voided volumes in subjects with excessive salt intakes as opposed to in those with low salt intakes18. In addition, we also found that the OAB symptom scores for the daytime frequency, nighttime frequency, urinary urgency, and urge incontinence (which were determined using the Core Lower Urinary Tract Symptom Score questionnaire19) were significantly worse in a group of patients with high salt intakes as compared to in a group of patients with low salt intakes18. Another prospective study showed that reducing the salt intake might improve nocturia and the OAB symptoms12. Hence, we speculated that there may be a relationship between OAB and excessive salt intakes. However, the aforementioned studies did not specifically focus on patients with OAB, and thus, we designed this study to evaluate the efficacy of restricting the salt intake in patients with OAB whose salt intakes were excessive.

The mechanism underlying the development of OAB due to excessive salt intake remains unclear. However, certain studies have provided some insight into it. In one study, the voided volume of spontaneously hypertensive and salt-sensitive rat models with an excessive salt intake decreased, while their urinary frequency increased after receiving a hyper load of salt13,14. Furthermore, Kurokawa et al. reported that the symptoms associated with urine storage may be induced by increased levels of adenosine triphosphate (ATP) and prostaglandin E2 (PGE2) that are caused by the suppression of the bladder’s blood flow in salt-sensitive rats fed with a high-salt diet14. They also reported that the increase in the release of ATP and PGE2 from the urothelium due to bladder stretching is likely to play a crucial role in storage dysfunction via stimulation of the bladder afferent c-fibers. In addition, several investigators have reported that excessive salt intake is associated with an imbalance between the sympathetic and parasympathetic activities, which affects the urinary condition20,21.

Excessive oxidative stress is associated with OAB symptoms. The relationship between oxidative stress and excessive salt intakes has been thoroughly researched in animal models, and it is believed that excessive oxidative stress, which could be caused by a high salt intake, may affect the OAB symptoms22,23. Briefly, in vivo and in vitro studies’ have shown that oxidative stress alters the physiological function of the urothelium and increases bladder sensitivity or the sense of urgency and that the high salt intake is associated with excessive oxidative stress24. Moreover, findings from basic research have shown that a high salt loading induces urinary storage dysfunction by upregulating the epithelial Na channel in the bladder epithelium of Dahl salt-sensitive rats13. Thus, we believe that complex mechanisms regulate urinary urgency and urinary incontinence secondary to excessive salt intakes.

Many patients with MetS and lifestyle-related diseases that are closely associated with OAB, including hypertension and diabetes, are salt sensitive25,26,27. Interestingly, some normotensive individuals are considered salt-sensitive, and their blood pressures increase after a high salt intake28.

Salt sensitivity may be enhanced by the presence of angiotensinogen M235T (T allele), α-adducin Gly460Trp (Trp allele), aldosterone synthase C-344T (T allele), or G protein β3 C825T (T allele) polymorphisms29. The Japanese tend to be more salt sensitive as compared to the other ethnic groups29. Hence, many patients in our study may have been salt sensitive, and their OAB symptoms may have disappeared when their blood pressure and blood glucose levels stabilized. Unfortunately, there are no tools available for use in a clinical setting that can predict the presence or absence of salt sensitivity in humans.

A previous prospective study showed that while excessive fluid intakes exacerbated the symptoms associated with OAB, restricting the fluid intake alleviated these symptoms and reduced the frequency of detrusor overactivity7,30. In addition, in our current study, it is possible that the OAB symptoms were relieved in patients who succeeded in reducing their salt intake due to a decrease in the water and salt intakes. As noted above, various mechanisms may improve OAB symptoms secondary to excessive salt intake. In fact, in the R group, the voided volume increased by approximately 12.6 mL, which was a statistically significant improvement; however, the magnitude of a clinically meaningful improvement in terms of patient satisfaction remains unclear. Previous large-scale clinical trials have reported that the administration of β3-adrenergic receptor agonists and anticholinergic agents to patients with OAB increased the voided volume by 13.07–39.52 mL31,32. Hence, the efficacy of salt reduction in terms of increasing the voided volume may be slightly weaker than the efficacy of medication therapy. Furthermore, even in the R group, the OABSS for urinary urgency (an essential symptom of OAB) was only improved by approximately 0.3 points. In this study, 67.6% of the patients in the R-group were on medications for OAB; 14 of these (29.2%) experienced an improvement in urgency as opposed to the 10 patients (43.5%) who were not on medication (P = 0.023). As a result, after the 12-week study period, only 23.9% of the patients who successfully reduced their salt intake did not meet the criteria used to diagnose OAB at the beginning of the study. Hence, a single behavioral therapeutic intervention and medications, especially for refractory symptoms, are not sufficient for treating OAB; OAB should also be managed using comprehensive treatment programs.

There were some limitations to our study. First, the number of participants was relatively small, and we did not include a placebo control group. However, this is the first study to evaluate the efficacy of salt intake reduction in the management of patients with OAB. Furthermore, it would be impossible to conduct a randomized, placebo-controlled study on salt intake levels due to taste concerns and the effects on human health. In addition, we did not investigate, in detail, the effects of successful salt reduction on systematic comorbidities (including the blood pressure and BMI), oxidative stress, and neurotransmitters. Changes in these parameters, secondary to salt restriction, might influence the improvement of OAB. As a future direction, evaluation of the changes in the oxidative stress, blood pressure, and hormones due to salt intake reduction is important to validate our results. Moreover, we will have to investigate the ongoing effects of restricting the salt intake by studying larger populations of patients for longer periods, such as 3 years or more. In addition, we must also investigate the influence of other internal OAB-associated factors, such as the gut microbiome and serum serotonin levels33,34, on the salt-dependent urinary function.

Finally, it is important to emphasize that reducing the salt intake for managing OAB is a pharmaceutical-free, safer, and more economic approach as compared to medication and surgery. This approach would minimize the risk to health in most individuals; it is beneficial for many different diseases and could improve survival and the quality of life. Hence, we believe that salt intake reduction should be recommended for patients with OAB in routine medical practice.


Our study showed that restricting the salt intake can improve urinary symptoms and the overall health of patients with OAB who have an excessive salt intake. Although the biological mechanisms underlying these findings are not fully understood, we suggest that salt intake reduction be recommended before conventional treatments are administered to these patients, because it is a safe and beneficial intervention for human health, and rules out the costs associated with pharmaceutical treatments.

Data availability

Data is available for revision.


  1. 1.

    Abrams, P. et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 21, 167–178 (2002).

    Article  Google Scholar 

  2. 2.

    Chen, G. D. et al. Prevalence and correlation of urinary incontinence and overactive bladder in Taiwanese women. Neurourol. Urodyn. 22, 109–117 (2003).

    MathSciNet  Article  Google Scholar 

  3. 3.

    Stewart, W. F. et al. Prevalence and burden of overactive bladder in the United States. World J. Urol. 20, 327–336 (2003).

    CAS  Article  Google Scholar 

  4. 4.

    Milsom, I. et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 87, 760–766 (2001).

    ADS  CAS  Article  Google Scholar 

  5. 5.

    Peyronnet, B. et al. A comprehensive review of overactive bladder pathophysiology: On the way to tailored treatment. Eur. Urol. 75, 988–1000 (2019).

    Article  Google Scholar 

  6. 6.

    Olivera, C. K. et al. Nonantimuscarinic treatment for overactive bladder: A systematic review. Am. J. Obstet. Gynecol. 215, 34–57 (2016).

    CAS  Article  Google Scholar 

  7. 7.

    Hashim, H. & Abrams, P. How should patients with an overactive bladder manipulate their fluid intake?. BJU Int. 102, 62–66 (2008).

    Article  Google Scholar 

  8. 8.

    Dallosso, H. M., McGrother, C. W., Matthews, R. J. & Donaldson, M. M. K. Nutrient composition of the diet and the development of overactive bladder: A longitudinal study in women. Neurourol. Urodyn. 23, 204–210 (2004).

    Article  Google Scholar 

  9. 9.

    Dallosso, H. M., Matthews, R. J., McGrother, C. W., Donaldson, M. M. & Shaw, C. The association of diet and other lifestyle factors with the onset of overactive bladder: A longitudinal study in men. Public Health Nutr. 7, 885–891 (2004).

    Article  Google Scholar 

  10. 10.

    Soltani, S., Kolahdouz Mohammadi, R., Shab-Bidar, S., Vafa, M. & Salehi-Abargouei, A. Sodium status and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Crit. Rev. Food Sci. Nutr. 28, 196–206 (2017).

    Google Scholar 

  11. 11.

    Sarebanhassanabadi, M. et al. Effect of dietary habits on the risk of metabolic syndrome: Yazd Healthy Heart Project. Public Health Nutr. 21, 1139–1146 (2018).

    Article  Google Scholar 

  12. 12.

    Matsuo, T., Miyata, Y. & Sakai, H. Effect of salt intake reduction on nocturia in patients with excessive salt intake. Neurourol. Urodyn. 38, 927–933 (2019).

    CAS  Article  Google Scholar 

  13. 13.

    Yamamoto, S. et al. High salt loading induces urinary storage dysfunction via upregulation of epithelial sodium channel alpha in the bladder epithelium in Dahl salt-sensitive rats. J. Pharmacol. Sci. 135, 121–125 (2017).

    CAS  Article  Google Scholar 

  14. 14.

    Kurokawa, T. et al. Underlying mechanisms of urine storage dysfunction in rats with salt-loading hypertension. Life Sci. 141, 8–12 (2015).

    CAS  Article  Google Scholar 

  15. 15.

    Homma, Y. et al. Symptom assessment tool for overactive bladder syndrome–overactive bladder symptom score. Urology. 68, 318–323 (2006).

    Article  Google Scholar 

  16. 16.

    Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension. Guidelines for the Management of Hypertension for General Practitioners. Hypertens Res. 24, 613–634 (2001).

  17. 17.

    Tanaka, T. et al. A simple method to estimate populational 24-h urinary sodium and potassium excretion using a casual urine specimen. J. Hum. Hypertens. 16, 97–103 (2002).

    CAS  Article  Google Scholar 

  18. 18.

    Matsuo, T., Miyata, Y. & Sakai, H. Daily salt intake is an independent risk factor for pollakiuria and nocturia. Int. J. Urol. 24, 384–389 (2017).

    CAS  Article  Google Scholar 

  19. 19.

    Homma, Y., Yoshida, M., Yamanishi, T. & Gotoh, M. Core Lower Urinary Tract Symptom score (CLSS) questionnaire: a reliable tool in the overall assessment of lower urinary tract symptoms. Int. J. Urol. 15, 816–820 (2008).

    Article  Google Scholar 

  20. 20.

    Fujita, M., Ando, K., Nagae, A. & Fujita, T. Sympathoexcitation by oxidative stress in the brain mediates arterial pressure elevation in salt-sensitive hypertension. Hypertension 50, 360–367 (2007).

    CAS  Article  Google Scholar 

  21. 21.

    Fujita, M. et al. Sympathoexcitation by brain oxidative stress mediates arterial pressure elevation in salt-induced chronic kidney disease. Hypertension 59, 105–112 (2012).

    CAS  Article  Google Scholar 

  22. 22.

    Nocchi, L., Daly, D. M., Chapple, C. & Grundy, D. Induction of oxidative stress causes functional alterations in mouse urothelium via a TRPM8-mediated mechanism: Implications for aging. Aging Cell 13, 540–550 (2014).

    CAS  Article  Google Scholar 

  23. 23.

    Suskind, A. M. The aging overactive bladder: a review of agingrelated changes from the brain to the bladder. Curr. Bladder Dysfunct. Rep. 12, 42–47 (2017).

    Article  Google Scholar 

  24. 24.

    Hattori, T. et al. Dietary salt restriction improves cardiac and adipose tissue pathology independently of obesity in a rat model of metabolic syndrome. J. Am. Heart Assoc. 3, e001312. (2014).

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  25. 25.

    Fujita, T. Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome. Hypertension 55, 813–818 (2010).

    CAS  Article  Google Scholar 

  26. 26.

    Kimura, G., Dohi, Y. & Fukuda, M. Salt sensitivity and circadian rhythm of blood pressure: The keys to connect CKD with cardiovascular events. Hypertens. Res. 33, 515–520 (2010).

    Article  Google Scholar 

  27. 27.

    Kuroda, S. et al. Role of insulin resistance in the genesis of sodium sensitivity in essential hypertension. J. Hum. Hypertens. 13, 257–262 (1999).

    CAS  Article  Google Scholar 

  28. 28.

    Morris, R. C. Jr., Schmidlin, O., Sebastian, A., Tanaka, M. & Kurtz, T. W. Vasodysfunction that involves renal vasodysfunction, not abnormally increased renal retention of sodium, accounts for the initiation of salt-induced hypertension. Circulation 133, 881–893 (2016).

    Article  Google Scholar 

  29. 29.

    Katsuya, T., Ishikawa, K., Sugimoto, K., Rakugi, H. & Ogihara, T. Salt sensitivity of Japanese from the viewpoint of gene polymorphism. Hypertens Res. 26, 521–525 (2003).

    Article  Google Scholar 

  30. 30.

    Swithinbank, L., Hashim, H. & Abrams, P. The effect of fluid intake on urinary symptoms in women. J. Urol. 174, 187–189 (2005).

    CAS  Article  Google Scholar 

  31. 31.

    Chapple, C. R. et al. The effects of antimuscarinic treatments in overactive bladder: An update of a systematic review and meta-analysis. Eur. Urol. 54, 543–562 (2008).

    CAS  Article  Google Scholar 

  32. 32.

    Nitti, V. W. et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J. Urol. 189, 1388–1395 (2013).

    CAS  Article  Google Scholar 

  33. 33.

    Okamoto, T. et al. The association between serum serotonin levels and overactive bladder: results from a community-based cross-sectional study in Japan. World J. Urol. Online ahead of print. (2020).

  34. 34.

    Okamoto, T. et al. Altered gut microbiome associated with overactive bladder and daily urinary urgency. World J. Urol. Online ahead of print. (2020).

Download references


We had no funding for this study.

Author information




Y.Mi. contributed to conceptualization and T.M. and Y.Mi planned study design. T.M., A.O., and Y.Mu. collected the data. T.M., Y.Mi., K.M., and K.O. performed data analysis. T.M. and Y.Mi wrote the main manuscript text and Y.Mi prepared Table 1 and 2. H.S reviewed and edited the manuscript. All authors reviewed and approved the final manuscript.

Corresponding author

Correspondence to Yasuyoshi Miyata.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Matsuo, T., Miyata, Y., Otsubo, A. et al. Efficacy of salt reduction for managing overactive bladder symptoms: a prospective study in patients with excessive daily salt intake. Sci Rep 11, 4046 (2021).

Download citation


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links